Template:Pyrazinamide: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical pharmacology|Clinical Pharmacology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide indications and usage|Indications and Usage]] | ||
| Line 19: | Line 17: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide how supplied|How Supplied]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Pyrazinamide how supplied|How Supplied]] | ||